I. INTRODUCTION Imagine a day when our fear of terminal illness no longer exists. Pretend for a moment that geneticists can mend our tragedy with their knowledge and skill. Are these scenarios plausible for our future? Should we struggle to make this reality even if it means giving up a part of ourselves and the formula of the human race? 2 If the answers to these questions are affirmative, then perhaps the efforts via the Human Genome Project (HGP) 3 and related biotechnology. patent laws are serving us well. However, if the answers are negative, perhaps the steps which are being taken to reach these objectives must be better authenticated by balancing ethical concerns with economic incentives for researchers through strategic legislation and patent law modification.
Part I1 of this note will explore the history of the HGP, while noting critical developments in the multinational project. Particularly, part II will provide scientific information on genetics and its vocabulary as a predicate to recent advances that are related to disease research, and specifically gene therapy research. In part Ill, biotechnology patent laws in Europe and the United States will be traced across time, while highlighting the present status of biotechnology patent law in both places. International ethical concerns relating to gene patenting as applied to disease research will be weighed against the necessary economic incentives for researchers in part IV of this note. Part V will discuss how biotechnology patent law in Europe and the United States implicates disease research, focusing on the impact broad patents may have on this area of science. Lastly, part VI will provide suggestions for patent law modification and legislative intervention to prevent the inhibition 2. The formula for the human race can be equated to the human genome sequence. The draft version of the human genome was published in 2000. See The Human Genome, ECONOMIST, July 1-7, 2000, at 1. Contrary to the earlier hypothesis that the human genome consisted of approximately 140,000 genes, scientists have concluded it may consist of only of disease research while simultaneously acknowledging ethical concerns and the need for economic incentives.
H. BACKGROUND AND DEVELOPMENTS

A.
Genetics Lesson
Understanding Gene Expression
The genome, which is divided into sequences of DNA 4 known as genes, encodes the information for polypeptide 5 sequences of protein and codes the information for its own gene expression. 6 The replication and expression of a cell's hereditary information makes up the totality of a cell's genetics. 7 It is gene expression that manifests human physical characteristics and disease. Therefore, the genetic processes within a cell should be understood before the logistics of the HGP and the related controversy over gene patenting pursuant to disease research can be appreciated.
The genetic processes within a cell include DNA replication,' transcription, 9 and translation." 0 The ultimate goal of these processes is protein synthesis." The purpose of DNA replication is to synthesize new DNA 4. DNA is a macromolecule that is double-stranded, helical-structured, and contains a cell's hereditary information. See RONALD M. ATLAS, PRINCIPLES OF MICROBIOLOGY 235 (Win.
C. Brown Publishers, 2d ed. 1996). It consists of "subunits," or nucleotides, which are arranged in a specific order. See id. The order of the nucleotides illustrates the cell's genetic information and contains the mechanisms that control gene expression. See id.
A polypeptide is "
[a] chain of amino acids linked by peptide bonds, but of lower molecular weight than a protein." Id. at 1229. The number and order of the amino acids within a polypeptide chain are significant because they determine both the structure and functional properties of protein molecules. See id. at 1182.
6. See id. at 280. 7. See id. at 234. 8. DNA replication is a precise process that entails synthesizing daughter DNA molecules that have the same nucleotide sequence as the parental genome. See id. at 235.
9. Transcription is the synthesis of relevant RNA (mRNA, rRNA, and tRNA) from a DNA template. See id. at 1241. A template is " [a] pattern that acts as a guide for directing the synthesis of new macromolecules." Id. at 1240.
10. See generally id. Translation is " [t] he assembly of polypeptide chains with mRNA serving as a template." Id. at 1242.
11. See id. at 273. Protein synthesis, the creation of proteins, occurs during the process of translation. See id. These formed protein molecules are important because they can functionally express genetic information. See id. The relationship between DNA, RNA, and protein was discovered in 1953 and is often is illustrated in diagram form: 12. Nucleotides are the "building blocks of nucleic acid." See id. at 14. DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) are both specialized types of nucleic acids. See id. Nucleotides consist of a phosphate group and either a purine or pyrimidine base. See id. The union of a large number of nucleotides is known as a polynucleotide. See id. DNA and RNA consist of long polynucleotide chains. See id.
13. Matthew Meselson and Franklin Stahl of the California Institute of Technology offered proof that DNA replication occurred semiconservatively. See id. at 23. The two scientists first grew cultures in an environment which contained heavy isotopes of carbon (1 3C) and nitrogen (15N). See id. Thus, the DNA in the cells grown in the "heavy" culture was heavier than the DNA grown in a "lighter" environment, containing natural isotopes of carbon (12C) and nitrogen (14N). See id. Because the heavier DNA had a higher density, it could be separated from the lighter DNA via centrifugation, a scientific procedure that involves high speed spinning to separate two substances with different densities. See id. Upon its separation, the cells containing "heavy" DNA were placed in the "light" medium, where it was allowed to multiply for one generation. See id. DNA with a density half way between the "heavy" and "light" densities of the original DNA replaced the "heavy" DNA, thus indicating that replication is not a conservative process where complimentary strands of the double helix stay together throughout the process. See id. Rather, it is a serniconservative process where the two strands separate during replication and each serve as templates for two new daughter strands. See id.
14. See ATLAS, supra note 4, at 244. 15. See id. at 264. 16. The strand of DNA, which is used for the synthesis of RNA, is commonly known as the "sense strand." See id. at 258.
17. RNA is a single strand of ribonucleotides that acts as an "informational mediator" between DNA containing stored genetic information and proteins which functionally express this information. See id. at 259.
18. See id at 258. Specifically, it is messenger RNA, or mRNA, which contains the code which is transcribed from the DNA and which will be "used to specify a sequence of amino acids in protein synthesis." See id. at 260. It is transfer RNA, or tRNA, which decodes the mRNA sequence, translating it into a correct amino acid sequence. See id. at 261.
19. See id at 264. Translation utilizes the RNA produced through transcription." Specifically, the RNA molecules act as templates, which order the amino acids within polypeptide chains of proteins.
2 " Ultimately, translation provides protein molecules with genetic information that they can functionally express. 23 
The Genetic Basis for Human Disease
Disease is linked to mutation, or the permanent change of DNA. 24 Mutations that affect the germ cells 25 may give rise to inherited disease since the information is passed from the parent to the offspring. 26 Mutations that occur in somatic cells 27 play an important role in the origin of cancer. 
3°3
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Developments in Gene Therapy
One aspect of disease research focuses on gene therapy. First attempted in 1990,31 gene therapy has primarily been used to treat a condition known as severe combined immune deficiency, or SCID. 32 The condition results from an adenosine deaminase (ADA) deficiency, which is an inherited genetic disorder. 33 Those children who lack the gene for ADA develop SCID, causing harm to their lymphocytes, ultimately preventing the immune response. 4 In order to treat this condition, scientists isolate damaged lymphocytes, extract the DNA, add the gene for ADA to the damaged cells via recombinant DNA technology, and inject these cells back into the patient. 35 Expression of the ADA allows for development of the once missing immune response. 36 While success has been limited for gene therapy, 37 scientists continue to use varied strategies on major diseases. While the list of diseases is numerous, Fighting Disease with Gene Therapy, http://www.bio.Indiana.edu/studies/ungradALl04AKInytimesSS100697.html (Oct. 6, 1997). Ex-vivo gene therapy, which is both expensive and complex, entails removing a cell from an individual and in turn infecting that cell with a virus which has been modified through the addition of a gene that will carry out a specific job within the body. See id. The cell that has been changed is then injected back into the patient, such that the added gene will hopefully carry out its job. See id. In-vivo gene therapy, which is much cheaper than ex-vivo gene therapy, involves the direct insertion of a virus, which has been disabled of its harmful effects and has been combined with a gene that will perform a specific task. See id. Once injected into the patient, the patient's body absorbs the modified DNA at the time when the disease in question becomes a threat, preventing the disease from being manifested. 45. See id. Beneath the sub-heading "Mendel and Pea Counting," the author explores mathematician-monk Gregor Mendel's work on garden peas. See id. His efforts in breeding peas gave birth to the notion that inheritance is quantitative, as it consists of "factors," which determine the manifestation of certain physical characteristics. See id. "Mendel correctly postulated that two copies of each factor are present in each of the parents and only one copy of each factor in the sex products -the 'gametes', or egg and sperm (pollen in plants) respectively." Id.
46. See ATLAS, supra note 4, at 28-29. James Watson and Francis Crick relied on the simple laws of structural chemistry, their intuition, and the examination of existing evidence to deduct that DNA is a double helical structure. They hypothesized that DNA was helical and accordingly used DNA X-ray diffraction patterns to test this educated guess. Further, they also built models to test their belief that DNA is helical. The often less mentioned scientists, Franklin and Wilkins, also played a role in developing the structure of DNA. See Macer, supra note 3.
47. The NIH was founded in 1887 and today serves as the "focal point" for U.S. medical research with the mission of discovering knowledge that will lead to better health for all. See U.S. Department of Health and Human Services: National Institute of Health, Questions and Answers about NIH, http://www.nih.gov/aboutFaqs.htm#NIH (last visited Oct. 2000). The goal of the NIH is to "help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold." Id. It carries out its mission by "conducting research in its own laboratories; supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad." Id.
48. See Macer, supra note 3. With finances, time, and efforts from around the world being utilized to further the project, the question arises: "Whose DNA is being sequenced?"'" For all practical purposes, it is every human being's DNA that is being sequenced. 52 While the DNA that is being sequenced is a combination of various human tissue cell lines, the outcome will represent the sequence of our species as humans rather than one specific individual. 53 Ultimately, all human beings will be able to say that the sequence is ninety-nine percent similar to their own. 4 In 2000, HGP scientists announced that they had a rough draft of the human genome, or the DNA located in a human cell.
5 Thus, the basis for the HGP goal, which was to "establish physical gene maps of all twenty-four unique human chromosomes in order to create a framework for understanding the genetic bases for human ... disease," seemingly has been established.
56
Now the eyes of all nations turn toward the future. While scientists may now have the human genome draft, applying this knowledge to prevent or cure disease will require even more effort. 57 Sydney
Brenner, director of the Molecular Sciences Institute in Berkley, California, warns that individuals should not expect a "quick payoff." 5 " In fact, when Brenner was asked about the use of this information for the future, he pointed out that it was a "big leap from just having the raw sequence to an 57. See generally The Human Genome: Ingenious Medicine, supra note 36, at 5-6. This article suggests that scientists may soon be working extensively in the area of proteomics. See id. at 5. Essentially, proteomics would require scientists to focus on the proteins themselves. See id. In fact, earlier this year, Celera Genomics raised almost $1 billion for the project of identifying the human proteome, which is analogous to the sequencing of the human genome. See id.
Oz Hopkins Koglin, Genome Sequence Just One Small
Step, Expert Says, OREGONIAN, September 27, 2000, available at LEXIS, Oregonian File. While Brenner does not believe that the newly sequenced genome is a "revolution," he does point out that it will accelerate research. See id. When asked about gene therapy, he expressed that he believed the better approach would be to study stem cells (the parent cells of all bodily tissues) rather than genes. See id.
[Vol. 12:1 EVOLVING BIOTECHNOLOGY PATENT LAWS interpretation of it." ' 59 Overall, the HGP has spawned issues in the area of patent law, leading to an international dispute over the desired status of patent laws.
C. The Gene Patenting Debate
The controversy over gene patenting began in early 1992, when the NIH filed two controversial patent applications for over two thousand partial gene sequences, which Dr. Craig Venter, an HGP researcher for the NIH, identified.'" Many critics of the NIH believed that the grant of patents on partial gene sequences would inhibit necessary communication between the HGP scientists. 6 Ultimately, the U.S. Patent and Trademark Office (USPTO) rejected the two applications, and the NIH, which gave in to the criticism, failed to appeal, reversing its gene patenting policy and refusing to pursue the patent applications further. 62 The gene patenting debate has become more complex since the NIH filed the controversial patent applications in 1992. In fact, the growing concerns over gene patenting are reflected in the evolving patent laws in the United States and Europe.
III EVOLVING PATENT LAWS
A.
What is a patent?
A patent is "a piece of paper signifying a grant to the inventor of certain rights. 63 There is a common misunderstanding that patents grant an inventor the right to do anything with her invention.M In fact, it does not give the inventor the right to make, use, or sell her invention.
6 ' The inventor's right to practice her invention is an inherent common-law right, which she has without a patent, as long as her practice does not infringe upon others' rights. ' (2000); See id. This change in patent term length afforded many advantages. First, the change in the patent term provided for consistency among other international patent systems, including Europe and Japan. See Wright, supra. Secondly, as the author contends, the twenty-year patent term is favorable to biotechnology research since it provides for longer patent protection. See id. Third, the twenty-year term reduces the "'submarine patent" problem. See id. When an inventor intentionally prolongs the application process to prevent the patent from issuing, the patent application becomes a submarine patent. See id. Often, companies will allow an industry to use its invention before the patent is issued, wait until the industry relies on the invention, and later demand royalties after the patent has been granted. See id.
[Vol. 12:1 EVOLVING BIOTECHNOLOGY PATENT LAWS cause of action against those who infringe upon her patent. 7 " This protection is especially important in biotechnology fields because the research involved is costly and time consuming." However, before a biotechnology patent can be obtained, the invention must meet the statutory requirements of patentable subject matter. In addition, other factors, which have drastically changed the U.S. patent law system, must be considered.
Statutory Requirements a. Utility
The United States Code defines the requirement of utility for an invention to be patentable by stating, "[wihoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title." 77 In order to satisfy the statutory requirement of utility, the claimed invention must be operable and have practical use." Operability means that the invention must be "capable of being used to effect the object proposed" in the specification. 79 The requirement of practical utility proposes the question of whether at least one objective described in the invention can be obtained by the claimed invention and then asks whether some more "specific benefit exists in currently available form. does not yet offer a "diminished" type of patent, which is often available in other countries. See id A diminished patent, contrary to a U.S. provisional patent, is redueed in term and examination compared to a utility patent. See id. Brenner involved claims related to processes that produced steroid compounds. The USPTO denied Manson a patent on the process in question because his application failed to disclose any utility for the steroid compound which the process produced, yet it was known in the art that the class of steroids which the product belonged to were potentially useful for tumorinhibiting effects in mice. 83 Despite Manson's argument on appeal that this product would be helpful in future research, the Supreme Court held that Manson's invention did not meet the statutory requirement of utility since the product was disclosed as being useful only "as a possible object of scientific inquiry.""
The utility requirement presents issues when inventors attempt to patent biotechnology, particularly genes. Genes have satisfied § 101 based on diagnostic utility. 85 Genes that have been discovered for diseases, like cystic fibrosis, have been patented because disease diagnostics itself is of utility. However, certain gene discoveries that lack immediate use for disease therapy are often found to lack utility, 8 7 as in the Brenner decision. Ultimately, the case law definition of utility has great impact on gene patenting. 88 
b. Novelty
An invention must also meet the requirement of novelty, which essentially requires that the patent applicant be the individual who first brought the invention to society's attention. 9 Specifically, 35 U. S. C. § 102 sets forth a variety of situations that would preclude an individual from obtaining a patent. Some of those instances include:
(1)"the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country.. ." (2) "the invention was patented or described in a printed publication in this or a foreign country. . ." (3) "he has abandoned the invention" (4) "the invention was described in a patent granted on an application for patent by another filed in the United States before the case of recombinant processes or genetic engineering that ultimately produces the same known product. 9 " Because inventions may be based on the "duplication of compounds that are found in living organisms or are produced by naturally occurring plants or animals," the product of nature doctrine is particularly important in the area of biotechnology. 93 In re Bergstrom' illustrates a situation in which the product of nature doctrine was circumvented. The court in In re Bergstrom analyzed whether purified and separated prostaglandin compounds isolated from tissue constituted a novel invention. The court found the materials that were purified differed from the same material which was less pure in its natural state. Thus, the court held that the pure materials were "new" with respect to the natural compound and thus satisfied the novelty requirement. 95 c.
Non-Obviousness
An invention must also meet the requirement of non-obviousness before it can be considered patentable subject matter. The United States Code states:
A patent may not be obtained ... if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains."
In Amgen Inc. v. Chugai Pharm. Co. Ltd., " a patent infringement case, the court had to determine whether a patent on a purified and isolated DNA sequence and host cells transformed with this DNA sequence were valid under § 103. The prior art generally taught that the use of fully degenerate probes of high redundancy could be used to screen a human genomic library.
The inventor used a known baboon EPO gene as a probe, which had been thought to be unsuccessful to those of high skill in the art. In determining the patent's validity under §103, the court used an "obvious to try" and "reasonable expectation of success" analysis in finding the patent to [Vol. 12:1 EVOLVING BIOTECHNOLOGY PATENT LAWS be non-obvious. 98 An expert witness for the inventor stated that the "overall homology of baboon DNA and human DNA was 'roughly 90 percent." '99 Citing this testimony, the court noted that while it may be feasible or even "obvious to try" probing a human gDNA library with a baboon cDNA probe, the reasonable likelihood of success was not certain.
°° Thus, the DNA sequence was not obvious; accordingly, the host cells containing this nonobvious sequence also met § 103.'0'
Factors Affecting U.S. Patent Law a. Creation of the Court of Appeals for the Federal Circuit
One of the initial markers of the U.S. patent law system evolution was the creation of the Court of Appeals for the Federal Circuit.' 02 Established on October 1, 1982, the court has exclusive jurisdiction of appeals from district court judgments in cases arising under U.S. patent laws and both direct and indirect appeals from decisions of the Patent and Trademark Office Board of Patent Appeals and Interferences.' 3 Prior to the creation of the U.S. Court of Appeals for the Federal Circuit, all patent infringement suits were tried in federal district courts with appeals being heard in one of eleven regional or circuit U.S. Courts of Appeal.' 4 The U.S. Supreme Court rarely granted certiorari from these courts.1 0 5
Two reasons prompted the formation of the Federal Circuit. First, early Supreme Court decisions seemed to reflect an anti-patent mentality."°6 At one point, the law required an invention be a "flash of creative genius"' 0 7 and to "push back the frontiers of chemistry, physics, and the like" in order to be patentable!" Congress overruled the "flash of creative genius" standard with 98 . See id. at 1208. The district court also used an "obvious to try" analysis coupled with a "reasonable expectation of success" analysis. Id. It ultimately determined that "there was no reasonable expectation of success in obtaining the EPO gene by the method .... Id Court briefly noted this standard, it seemed to revert back to its previous, more conservative views on patents in later cases. 110 Second, lower courts had issued extremely inconsistent decisions on patent issues. In fact, at one point a patent was almost four times as likely to be enforced in the Seventh Circuit than in the Second Circuit."' This led to confusion" 2 and forum shopping.' Ultimately, the creation of the Federal Circuit promoted uniformity" 14 in patent law while allowing specialized judges to hone a complex area of law. ' The Federal Circuit has had a noticeable effect on biotechnology patent law."
6 The Federal Circuit has displayed a "pro-patent" mentality quite Accepting the Justice Department's proposal, the U.S. Court of Customs and Patent Appeals and the U.S. Court of Claims were combined to form the Federal Circuit as a result of the Federal Courts Improvement Act. See PETERSON, supra, at 9. Congress hoped the new system, which has been called a "bold experiment," would help the United States compete internationally in the industrial arena. See BURCHFIEL, supra, at 10. 113. See PETERSON, supra note 63, at 9. Because some circuits had a seemingly hostile view toward patents while other circuits were considered patent-friendly, the practice of forum shopping began. See id. at 8. Those who owned patents attempted to have their cases tried in a jurisdiction that had a patent-friendly attitude. See id. at 9. Meanwhile, alleged infringers sought out patent-hostile circuits. See id. The combined uncertainty caused patents to lose their value. See id. Many chose to no longer seek patents because they did not want to invest in getting a patent when a hostile jurisdiction could quickly take it away. Seeid.
114. See BURCHFIEL, supra note 78, at 10. Congress definitely had national patent uniformity in mind when it created the Federal Circuit. See id. In its beginning, the Federal Circuit made it clear that any decision, other than its own, including the Supreme Court's earlier decisions inconsistent with the reasons that prompted the creation of the Federal Circuit, would all serve as merely persuasive authority. See id. Thus, the Federal Circuit has the power to remove the Supreme Court from any or all parts of the administration of the patent legal system. See id at 11. Since its creation, the Federal Circuit has succeeded in providing the much-needed uniformity in patent law nationwide. See id. See also PETERSON, supra note 63, at 10 (noting "substantial improvement" in uniformity on appeals for patent cases). 121. See id. Specifically, the author argues that legislation implementing GATT has had a huge effect on patent law. She also looks at legislation that was being proposed at the time she wrote the article. See id. The legislation, tided the Moorehead Bill, focused on publication of patent applications eighteen months after the earliest effective filing date. Wright, supra note 74. The author cites advantages and disadvantages to patent publication. Publication could be advantageous because it can promote innovation within the biotechnology field. See Wright, supra note 74. Early publication could prevent repetitive experiments while indicating areas of research containing positive results, deterring other researchers away from research "dead ends." See id. Publication could also provide inventors "prior art" status, cause potential submarine patents, which allow companies to "hide" their patent and later demand royalties, to be disclosed, and provide U.S. inventors with the opportunity to see information within patent applications filed abroad. See id. This is important since information in U.S. patent applications, which are also filed in a country with publication laws or under the Patent Cooperation Treaty, is disclosed eighteen months after filing. See id.
115.
122. See id.
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of the patent application via the GAIT enabling legislation. Provisional patent applications have also been created as a result of GATT legislation.' 27 These applications afford advantages specifically to small businesses because the process involves less cost and fewer legal requirements.'
28 Essentially, the provisional patent application ensures an inventor one year to carry out further research before he decides whether or not he wishes to invest in a more expensive non-provisional patent.' . The author contends that a twenty-year term could cause several attempts to delay the issuance of a patent, unlike the seventeen-year patent which the applicant receives no matter how long the process takes, ultimately discouraging others from interfering with the process. See id. In contending that the twenty-year patent may be delayed, the author predicts: (1) "Patent examiners would give lower priority to examining the more important patents or offer limited claims to get a patent issued because of the work involved and the risk of issuing a controversial patent." (2) "Those effected by the patent could enter into delaying tactics by giving prior art on the patent to the patent office at times most designed to delay a patents [sic] issuance. This tactic will be even more common if 18 month publication becomes law." Id.
126. See id. The author argues that patent applicants often have a great deal of uncertainty concerning their inventions and by adding to the length of the patent, the uncertainty is also extended. See id. This could be detrimental to innovation. See id.
127. See id. The only requirements for a provisional patent application are a specification, a cover sheet, and drawings. See id. However, the provisional patent application must be "enabling," such that a person of ordinary skill in the art could build or perform the invention/method from the detail specified in the application. See id.
128. See Wright, supra note 74. I. In general A. Proceedings. In proceedings in the Patent and Trademark Office, in the courts, and before any other competent authority, an applicant for a patent, or a patentee, may not establish a date of invention by reference to knowledge or use thereof, or other activity with respect thereto, in a foreign country other than a NAFTA country or a WTO member country, except as provided in sections 119 and 365 of this title. B. Rights. If an invention was made by a person, civil or military --1. while domiciled in the United States, and serving in another country in connection with operations by or on behalf of the United States, 2. while domiciled in a NAFrA country and serving in any other country in connection with operations by or on the behalf of that NAIFTA country, or 3.
while domiciled in a WTO member country and serving in another country in connection with operations by or on behalf of that WTO member country, that person shall be entitled to the same rights of priority in the United States with respect to such invention as if such invention had been made in the United States, that NAFrA country, or that WTO member country, as the case may be. a. Use of Information. To the extent that any information in a NAFTA country or a WTO member country concerning knowledge, use, or other activity relevant to proving or disproving a date of invention has not been made available for use in a proceeding in the Patent and Trademark Office, a court, or any other competent authority to the same extent as such information could be made available in the United States, the Director, court, or such other authority shall draw appropriate inferences, or take other action permitted by statute, rule, or regulation, in favor of the party that requested the information in the proceeding. 131. See Wright, supra note 74.
While the GATT legislation provided significant modifications to the patent law system, no major changes have occurred since 1953, which was the first change since the creation of the patent law system in the 1700s. 132 However, new legislation, titled the American Inventors' Protection Act (AIPA) 133 has overhauled the patent system. One representative stated that the purpose of the AIPA is "[t]o advance American technology, strengthen our nation's global competitiveness, and to reward inventors on a more timely basis.... ."l The AIPA has changed patent law in three major ways. One provision provides for optional limited contested reexamination, which ultimately allows for more third-party participation on reexamination of patents."' A second.important change is the provision for publication of U.S. patent applications. 1 36 Another important feature guarantees the term of the patent to compensate for USPTO delays.'
37
Critics of the AIPA have suggested that it will reshape the U.S. Patent System in favor of big corporations who want quicker access to invention information.' Specifically, many fear that the requirement, which demands publication after eighteen months, may promote others to steal invention ideas before the inventions are protected by a patent.' 39 However, these fears are combated by proponents of the AIPA who point out that this legislation could make patent laws more congruent with European and Japanese patent laws, increasing U.S. companies' ability to compete internationally. 136. See id. This provision is a significant change. See id. Previously, patent applications were held in confidence. See id. Now, if the inventor chooses foreign filing in addition to UPSTO filing, "all pending U.S. patent applications will be published at 18 months from the earliest convention or PCT filing date." id. Provisional royalties will be rewarded to the applicant between the times of publication and patenting as long as the patent issued reflects the claims published. See id.
137. See id. This guarantee for the term of a patent compensates for UPSTO delays from "interferences, secrecy orders or appeals, as well as when the PTO fails to grant the patent within three years." Id.
138. See Zwahlen, supra note 132, at 8. European patent law functions on many levels. It is important to initially note that there is no unitary European patent law system. 14 Thus, a discussion of European patent law is inclusive of a combination of European countries' national patent systems that all contain their own administrative and judicial history. 42 However, European patent law also contains many efforts to harmonise these European countries' patent systems through treaty efforts like the Paris Convention (PC),1 43 Patent Co-operation Treaty (PCT),'" and the European Patent Convention (EPC). 145 The discussion below will focus primarily on the EPC because it plays a definitive role in biotechnology business.
The EPC, a treaty among eighteen European nations, was created to promote European state collaboration regarding protection of patentable matter.
' 4 6 The EPC gave rise to the European Patent Office (EPO).
147
Essentially, the EPC allows an inventor to go through one office, the EPO, in order to obtain a bundle of national patents, which are subject to the corresponding national laws of the relevant EPC member states.' 48 Ultimately, an inventor who wants to obtain a patent on an invention in multiple European nations should file with the EPO, whereas an inventor seeking a patent in only a few countries should file directly with those nations' patent offices.
49
A positive result of the EPC has been the modification of some individual European nation's patent laws to correspond with neighboring nations.'" 0 While the EPC is not ensuring patent uniformity, it certainly is causing some positive movement towards supranational agreement.' 5 ' This prevents forum-shopping among states and lends hope to the ultimate goal of patent law uniformity among developed countries worldwide.' 5 2
Substantive Requirements for Patentable Material
The substantive requirements for patentable subject matter under EPC are slightly different than the statutory requirements which must be met under U.S. law. The substantive requirements under the EPC are: (1) novelty,' 53 (2) EPC). 2. The state of the art shall be held to compromise everything made available to the public by means of a written or oral description, by use, or in any other way, before the date of filing of the European patent application. 3. Additionally, the content of European patent applications as filed, of which dates of filing are prior to the date referred to in paragraph 2 and which were published under Article 93 on or after that date, shall be considered as compromised in the state of the art. 2001] money, it seems that third world countries have little voice at all. Thus, those countries that did not wish to have the genome identified for conflicting religious, philosophical, or cultural reasons, never had the chance to "opt out" of the research. While this ethical stop sign may be countered by the proposition that the HGP may someday provide the medical aid these third world countries need, ethical questions surrounding related gene patenting must be considered. Individuals in countries which are less developed than the United States and many of the European countries often have views on gene patenting that differ from developed countries. 2" ' Individuals from less developed countries often believe that intellectual property should belong to the public as a whole rather than to the private sector. 21 2 Moreover, they feel that gene patenting is interrupting nature and reducing life to a commodity. 213 Researchers justify their actions by pointing out that the individuals give consent and are compensated with royalties for their cell line donations. 21 4 However, this must be considered in light of third world poverty and the standard of education in these countries. One might expect individuals in third world countries to forego their cultural and moral beliefs if they do not have the educational foundation to comprehend what they are giving up. Moreover, even if these individuals understand that which they are giving the researchers, they may be so plagued by poverty that they will choose the royalties despite their belief system. In addition to cultural and moral concerns, there may also be social implications to consider. As scientists seek out genes from individuals from third world countries to study diversity as it relates to disease, 1 5 several fears arise. For instance, Jonathan King, a professor at MIT and member of the board of Council for Responsible Genetics states,
[w]e are concerned that the emphasis on gene sequences will be used to imply that genes are at the basis of a variety of human disease and conditions, when in fact the great body of evidence establishes that the majority of human ill health is not inherited but is due to external insult including pollution, infection, inadequate or inappropriate diet, physical accident, excess stress or social disruption such as wars. Preventing damage to human genes from carcinogens is a far more effective public health strategy than allowing the disease to develop and then attempting gene therapy. 2 The Indigenous Peoples Council on Biocolonialism 21 7 has developed a model ordinance to assist tribal governments on these types of matters. 218 Within this concern of exploitation of indigenous people lies an important topic also to be addressed, the Conunon Heritage Principal." 9 This ethical concern and the fear of exploitation of indigenous people are issues that should be considered before patent law is reformed.
One of the disputes over gene patenting arises from the question of how genetic property interests should be distributed." 2 2 Presently, the private sector in wealthy countries maintains control over much genetic material. Many argue that this is not appropriate because genetic material, in the case of the human genome, belongs to all of us through our ancestry.
21 Accordingly, the genome should be accessible to everyone under the international theory of the Common Heritage Principal. 2 If the Common Heritage Principal were applied to gene patenting, public consent would be mandatory before patents could be obtained. 223 It is important that all of the ethical concerns over gene patenting be weighed against the need for innovation and the corresponding necessary economic incentive.
B. Incentive & Innovation
Due to the efforts of the HGP, there seems to be increasing hope that this newly acquired knowledge will be applied positively to the field of medicine. However, the scientists who are attempting to find useful purposes for the HGP knowledge spend large amounts of time and money and therefore seek patents to protect their investment. 224 Because great medical benefits could arise through this research, and the known way to secure this research is via patents, one might argue that it is unethical to prohibit gene patents. Moreover, it seems fundamentally unfair to deprive hard-working researchers, who have the means to promote public health, from the possibility of receiving profits for their efforts.
While most would agree that scientific innovation should be promoted, the controversy on certain gene patents continues. The reward theory, an economic patent theory, proposes that without reward, inventors would have no incentive to invent. Such a discouraging market could ultimately decrease innovation since investors would no longer wish to expend energy to reach a low-profit outcome. This could be detrimental to biotechnology research.
V. BIOTECHNOLOGY PATENT LAWS AND DISEASE RESEARCH: BROAD PATENTS
As patent laws continue to evolve in the United States and Europe, becoming increasingly pro-patent, it is important to reflect upon the trends in the law and analyze their impact on disease research.
One product of 224. In the past, scientists have spent approximately seven billion dollars on research and development in the biotechnology industry. See Wright, supra note 74.
225. See Erramouspe, supra note 74, at 973. The author also discusses another economic patent theory known as rent dissipation theory. In discussing the rent dissipation process, the author argues:
[slome patents will confer rewards that exceed the inventor's development costs. Where these excessive rewards are expected, inventors will often compete with each other to be the first and only inventor to win the patent. These competitions can be socially unproductive because they often duplicate inventive activity and divert resources into the inventive sphere even though society would be better served were these resources used elsewhere. At a limit, the total net social benefit derived from an invention can be depleted entirely in a race to develop the invention quickly, perhaps too quickly. Id. at 976.
226. See id. at 973.
[Vol. 12:1 EVOLVING BIOTECHNOLOGY PATENT LAWS evolving patent laws is a broad patent."' This growing movement toward patent offices granting broad patents on biotechnology inventions is of great concern."' 5 A broad patent is a patent that covers a wide scope of innovation, rather than just a sole invention.1 29 Broad patents are often the goal of commercially-motivated companies since they can result in huge royalties from competing companies who seek licenses to use the patented inventions. 230 Many argue that this movement towards broad patents is having a detrimental effect on disease research.
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Broad patents can have negative consequences. 232 Because these patents are wide in scope, "stacking" of patent claims often occurs when multiple aspects of a biotechnology product are broadly patented. 233 This stacking means that researchers who do not hold the patent but who wish to use the information for further research must obtain corresponding "stacked" patent licenses. 23 ' Each of these licenses can cost huge dollars, often too much money for small corporations to afford. 3 5 The result for those who cannot afford the high costs means not entering this realm of research, simply hampering innovation.
2 36 For those who can afford the high costs, their dollars are spent on these expensive licenses or perhaps on legal counsel if they infringe upon the broad patent claims. Thus, in light of the changes in U.S. and European patent law, the ethical considerations of biotechnology patents, the necessity for incentive, and the desire for innovation, suggestions for legal reform can be discussed.
Presently, provisional applications allow inventors to secure up to a year of provisional patent protection if they are unsure of the invention's marketability. 2 4 ' After that year expires, inventors can secure a twenty-year patent term if they so desire. A reform of this system, by providing more kinds of provisional patents, each varying in the number of years of protection proportionate to the invention's anticipated level of utility and likelihood of development or marketability, could help promote innovation.
For example, imagine a small company seeking a provisional patent on a particular biotechnology invention whose further development is uncertain, while it is projected to be of high utility. Because of the high costs of traditional twenty-year patents, a company may wish to seek a provisional patent application,242 yet at the same time fear that the one-year provisional application period may not provide the time needed to decide if a twenty-year patent is warranted. At the end of the one-year, the company may prematurely enter into the twenty-year patent, 243 possibly contributing to patent "stacking" despite the invention's uncertainty. 2 " With a reformed provisional patent system, UPSTO or EPO could establish a system objectively measuring predictable utility, then measure the inventions possible utility and assign an according specific term of years for this provisional patent. This would ultimately give uncertain companies the time they need to explore all avenues before prematurely seeking a twenty-year patent that could exclude others from the invention for a long period of time. Ultimately, this could decrease the number of twenty-year patents being granted to uncertain inventions, and hopefully decrease the monopolization of biotechnology so that innovation can be maximized.
VII. CONCLUSION
Disease research provides hope of escape from threatening illnesses for future generations and ourselves. Thus, biotechnology patent laws should be reformed to parallel the importance of this research. While many argue that cures for cancer, AIDS, and other life-threatening diseases are years away, worldwide patent law systems should take appropriate steps to make sure that time is sooner rather than later. This means finding the best way to provide all researchers with the incentive to explore and discover, while promoting innovation worldwide. This is difficult to juggle, particularly when competing legitimate ethical concerns must be considered to prevent exploitation of indigenous people. 
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Legal patent reform is necessary to insure that disease research is maximized. Both the United States and Europe have recognized this need and are presently seeking a resolution. However, this resolution may be shortlived as technology advances quickly. Ultimately, in this constantly evolving process of attempting to establish a mirror between patent laws and technology, we must unite internationally to promote innovation, yet recognize the importance of all of our cultural, social, and religious value systems at the same time. [Vol. 12:1
